ARTICLE | Company News

Valentis cardiovascular, gene/cell therapy, cancer news

January 22, 2002 8:00 AM UTC

VLTS said it will suspend its clinical programs in oncology, reduce its preclinical R&D and reduce its headcount to 65 from 110 in efforts to lower its quarterly burn rate to $5 million from $9 millio...